Evonile Pharma

Offering a trusted portfolio of therapies for the management of acute and chronic pain, inflammation, and musculoskeletal disorders, supporting improved mobility and quality of life.

Ramesh Ramadurai brings over 35 years of global leadership experience at 3M, spanning across India, United States, Philippines and China most recently serving as Managing Director of 3M India. He holds a B.Tech from IIT Kanpur and an MBA from IIM Calcutta.

Bhagwat Singh Deora has over 20 years of experience in finance, risk management, and compliance in the pharmaceutical and healthcare industry. He previously worked as VP of Finance at JB Pharma and held leadership roles at Macleods Pharmaceuticals, Cipla, and PricewaterhouseCoopers.

Company Secretary & Compliance Officer Nodal Officer for coordination with IEPF Authority Chandni Maru

Chandni Maru Company Secretary & Compliance Officer

Evonile Pharma Limited dedicated to expanding the reach of high-quality healthcare solutions across the country.

The information contained on this website is provided by Evonile Pharma Limited for general informational purposes only.

Novartis rebrands its listed Indian subsidiary as **Evonile Pharma Limited**, effective October 1, 2026. The change follows regulatory approval from India’s Ministry of Corporate Affairs (MCA). The move consolidates Novartis’ local operations under a new corporate identity while maintaining its pharmaceutical business focus.

Oct 2026medicaldialogues.inNews article

ChrysCapital-backed **Novartis India** acquires **Pfizer’s Minipress**, a blood pressure medication brand. The deal supports Novartis India’s expansion strategy through acquisitions. Pfizer is divesting the brand as part of its portfolio optimization efforts.

Sep 2026VCCircleNews article

ChrysCapital completes its acquisition of a **70.68% controlling stake** in **Novartis India Ltd (NIL)** from Novartis AG, marking its first majority investment in India’s pharmaceutical sector. The deal solidifies ChrysCapital’s entry into the country’s pharma industry through a listed entity. ChrysCapital, a private equity firm, now holds a majority position in the Indian subsidiary of the Swiss pharmaceutical giant.

Jul 2026M&A Critique | THE WHYS AND THE HOWSNews article

Novartis AG sells its 70.68% stake in Novartis India for approximately **₹1,445.89 crore**. WaveRise Investments and ChrysCapital Fund X lead a **26% open offer** at **₹860.64 per share**, marking the Swiss pharma giant’s full exit from its Indian subsidiary. The transaction reflects strategic restructuring amid shifting global healthcare investments.

Feb 2026financialexpress.comNews article